FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4), which can be used in medicine. CTLA-4 polypeptide with mutations is obtained, as well as, its IgG Fc conjugate, a host cell for producing a polypeptide, a composition comprising the polypeptide, which are used to treat an autoimmune disease and / or weaken the response of T cells in a patient.
EFFECT: invention allows, due to the high affinity and stability of the polypeptide, to increase the effectiveness of the treatment of an autoimmune disease and / or weakening the response of T-cells in a patient, for example, rheumatoid arthritis.
24 cl, 7 dwg, 12 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS | 2008 |
|
RU2506275C2 |
| ISOLATED NUCLEIC ACID ENCODING FELINE LIGAND CD86, DIAGNOSTIC OLIGONUCLEOTIDE, CLONING VECTOR, VACCINE, METHODS FOR INDUCTION OR SUPPRESSION OF IMMUNITY IN CAT | 1999 |
|
RU2263145C2 |
| NUCLEIC ACIDS, CODING RECEPTOR CTLA-4 OF CAT, VECTORS, HOST CELLS, VACCINES, OLIGONUCLEOTIDES, POLYPEPTIDES CTLA-4 OF CAT AND METHODS FOR INDUCTION AND SUPPRESSION OF IMMUNE RESPONSE IN CAT | 1999 |
|
RU2377302C2 |
| INHIBITORS OF T-CELL ACTIVATION | 2012 |
|
RU2657440C2 |
| RECOMBINANT VIRUS EXPRESSING FOREIGN DNA ENCODING FELINE CD80, FELINE CTLA-4 OR FELINE CD86 AND ITS APPLYING | 1999 |
|
RU2244006C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
| METHOD FOR SELECTION AND OBTAINING OF HIGHLY SELECTIVE AND MULTISPECIFIC TARGETING GROUPS WITH SPECIFIED PROPERTIES, INCLUDING AT LEAST TWO DIFFERENT BINDING GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2639287C2 |
